88IV - PR Newswire Asia's news - Medical/Pharmaceuticals


Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia SHANGHAI , May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative ... 2026-05-06T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Nona Biosciences Evolves Brand to Reflect Next Phase of Growth in Biotherapeutic Innovation CAMBRIDGE, Mass. , May 6, 2026 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announ ced the launch of its ... 2026-05-06T Health Care/Hospital Medical/Pharmaceuticals
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026 GUANGZHOU, China , May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced ... 2026-05-06T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) HONG KONG , May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity ... 2026-05-06T Health Care/Hospital Medical/Pharmaceuticals
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1 PEDMARQSI ® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid ... 2026-05-06T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1 PEDMARQSI ® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid ... 2026-05-06T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
AI Model Analyses Body Composition to Predict Health Risks OAK BROOK, Ill. , May 5, 2026 /PRNewswire/ -- Researchers used AI to analyze whole-body MRI scans from more than 66,000 participants to create the most detailed reference map to date of how fat and muscle ... 2026-05-05T Health Care/Hospital Medical/Pharmaceuticals
Hidden Muscle Fat Poses Danger to Heart, Metabolism OAK BROOK, Ill. , May 5, 2026 /PRNewswire/ -- Using a deep learning model to analyze the composition of large muscles on MRI, German researchers found that the proportions of intermuscular fat and lean ... 2026-05-05T Health Care/Hospital Medical/Pharmaceuticals
BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms Recognition highlights BostonGene's leadership in improving drug development decisions, reducing risk and accelerating patient impact ... 2026-05-05T Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals
BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints SUZHOU, China , May 5, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its ... 2026-05-05T Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Medical/Pharmaceuticals